• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    TaiMed Biologics

    Syngene International Ltd.

    Quotient Sciences

    CMC Pharmaceuticals

    LOTTE BIOLOGICS
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    TaiMed Biologics

    Syngene International Ltd.

    Quotient Sciences

    CMC Pharmaceuticals

    LOTTE BIOLOGICS
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Extrusion-Spheronization in OSD Manufacturing

    How extrusion-spheronization excels delivering controlled and modified release dose forms.

    Extrusion-Spheronization in OSD Manufacturing
    Extrusion-Spheronization in OSD Manufacturing
    Holger Shen , Technical Services Manager, Bora Pharmaceuticals02.06.23
    In this article, we’ll explore how extrusion-spheronization (E-S) is applied in manufacturing, the sophisticated dose forms the process helps create, and why it supports the controlled delivery of active pharmaceutical ingredients (APIs) and ultimately improves patient outcomes.

    Manufacturing of oral solid dose (OSD) APIs leveraging E–S has gained favor because of the number of patient-centered benefits it provides formulators and drug developers. Because oral delivery is preferred, E-S is proving to be a versatile tool in finished drug product development, suitable for even the most complex OSD formulations and APIs, including new molecular entities (NMEs) and—life-cycle management extensions.

    Formulations engineered using E-S offer a predictable vehicle to control the distribution and delivery of therapeutic agents around the body. The method is most often applied to create amorphous solid dispersions (ASDs) of particles containing API. This allows for great latitude in designing the treatment’s oral delivery profile including E fixed-dose combinations, combined, modified release tablets and capsule forms, and multi-unit particulate system tablet designs.

    Pharma developers can take advantage of E-S to deliver high-throughput manufacturing, reduce waste during processing and improve yield. More importantly, because the methodology is so well understood, it provides the ability to control critical aspects of dosing complex APIs and formulations. The controlled, modified release E-S provides an effective, reliable means to manage API delivery effectively, managing treatment with less frequent individual doses over time.

    Extrusion Spheronization Explained?

    The E-S process is made up of four steps: wet granulation, extrusion, spheronization and drying/coating:

    •  Wet granulation sees the combination of API, excipients and binders, in addition to sterile water, added in the desired ratios, to create a wet granulation batch ready for extrusion. The goal of this part of the process is to create a wet, homogenous mass that is able to retain its shape under pressure with enough gliding properties to keep extrusion flowing.
    •  Extrusion is designed to produce extrudates suitable for spheronization. The process sees the forcing of the wet cake from a large diameter through to a small diameter. There are a number of specific technologies and equipment that manufacturers offer to achieve extrusion.
    •  Spheronization is a rotating/milling process that tumbles the wet cake extrudates into uniform spherical shapes. A spheronizer uses a spinning friction plate that generate centrifugal force and friction to create micro-collisions, which shape the cylindrical extrudates into spheres.
    •  Drying/coating sees the completion of the process, where the uniform spheres can be dried and/or subjected to a coating process to manage dose delivery goals, such as controlling API release or taste masking.

    Taking Advantage of Advanced Knowledge

    The spheronization stage was invented in 1964 by Norauo Nakahara and was subsequently commercialized under the trade name, “Marumerizer” – “maru” meaning round in Japanese. The innovation passed largely unnoticed until 1970 when articles on the process were published by employees of Eli Lilly.

    Since this time, the ability to apply E-S to increase therapeutic performance or modify API release, without having an impact on the integrity of the compound or molecule, has been made possible through developments across pharmaceutical science. The industry’s knowledge regarding raw materials and ingredients, as well as the processes and controls behind the methodology, have all advanced to the present point, where a high level of control can be ensured over the dynamics of extrusion and spheronization.

    By manipulating the blending of size and density during E-S, it is possible to control solubility and bioavailability—this, in turn, allows for the attainment of different release patterns over time. For manufacturers, this enables them to develop modified release dose forms, which can help to reduce or eliminate side effects common in other dosage forms, such as irritation of the gastrointestinal tract or to achieve release in the lower intestine.

    Patient Centricity Driving Drug Design

    There has been a shift across the industry in recent years to consider the patient first, which has led to “patient centricity” in drug development by placing the patient’s demands before all else. Increasingly the industry is emphasizing therapeutic value, adopting treatment approaches centered on improved patient health outcomes and a better overall patient experience.

    Regulatory agencies worldwide have also been involved in this push for great attention to be paid to patient’s voices in drug R&D. Under the Prescription Drug User Fee Act (PDUFA V), the Food and Drug Administration (FDA) organized 24 disease-specific Patient-Focused Drug Development (PFDD) meetings to gather patients’ perspectives on their condition and on the therapies available to them. The report covering all 24 meetings was released at the end of 2019.1 At the same time, in Europe, the European Medicines Agency (EMA) created its Patient Engagement Framework for guidance and thought leadership, with support from the European Patients’ Academy (EUPATI).2

    It has become an established part of the industry that regulators and drug developers are actively searching for more effective ways to incorporate patient reported outcomes. In this way, a collective understanding of the value that new or redeveloped therapies can bring to a specific modality or treatment area is recognized. The conclusion that has been drawn by all entities in the industry is that the happier patients are with their treatments, the more likely they are to continue with them and therefore the more likely they are to be effective—benefiting everyone and, ultimately, potentially lowering overall healthcare costs by encouraging a healthier population.

    Wider Than One Patient

    It is clearly apparent that the pharmaceutical industry is listening and acting on individual patients’ voice. It has also learned how to apply these lessons more broadly, to more patient groups, regardless of size or disease category. It is now expected that the intellectual property holders behind a treatment will develop or adapt to precisely meet the needs of different groups of patients, such as tailoring dose forms to better suit a population’s special needs and treat the condition more effectively.

    It is recognized that OSDs are the most popular for patients, as they are generally easier to swallow, require fewer doses to be effective over longer periods, and are able to reduce or avoid entirely unpleasant side effects.3

    For drug designers looking to develop patient centric OSDs, the finished dose forms that E-S can deliver are offering new flexibility and utility. Modified release formulations can be effective for providing drug substances that need to be in an OSD to ensure adherence to the treatment regime, and it can also be necessary for substances that have a narrow therapeutic index.

    Multi-particle, multi-sphere finished-dose forms are another way to provide patients with an effective treatment that can deliver complex patient-centric OSD drug strategies. Multi-particle systems are able to demonstrate higher levels of desired reproducible pharmacokinetics and pharmacodynamics, enabling improved therapeutic effects in patients.

    Why Extrusion-Spheronization Offers Efficiency

    E-S provides inherent efficiency, reliability and minimized variability. Due to the efficiencies related to drug loading and similar characteristics in formulation, the process generates economies on all fronts without diminishing quality.

    By comparison, single APIs often require dispersion throughout a solid matrix to control release. As a result of these matrices, there can be a limit to the rate at which active ingredients are dispersed into the body.

    The E-S process is also a reliable, flexible alternative to other spheronization or pellet agglomeration manufacturing techniques, such as coating or layering. Further, drug pelleting through E-S is known to be a much faster process than drug layering.

    Practical Applications

    In terms of what particular use cases E-S could prove to be invaluable, two examples serve to highlight the potential for drugmakers looking to improve the formulation of their treatments.

    In the first case, one company was struggling with its first-in-class oncology treatment that had issues with solubility and bioavailability. If it were delivered in regular, single-fixed release forms then patients would be forced to take the treatment three times per day. From a dose-compliance and therapeutic value perspective, this was not an option for the company. Through the use of E-S, the company was able to modify and control the release of the API over a longer period, as part of a multiple-unit pellet system form. Instead of being required to take a three-a-day treatment, patients could take one capsule that provided a controlled release of active ingredients over 24 hours.

    A second example saw a company facing the patent expiry of a key product and, as a result, they were looking to explore a 505(b)(2) life-cycle management strategy, involving integrating two proven but incompatible APIs into a single dose, controlled-release capsule. The aim was to provide a best-in-class therapy that improved patient outcomes and therapeutic performance against multiple doses of two medications. This was where E-S was able to provide a solution, by segregating and controlling previously incompatible APIs, alongside other functional ingredients in cohesive pellets, which could then be delivered within a single OSD form.

    Continuing Innovation Ahead

    Just because the technology has existed since the 1960s does not mean that development and refinement of the E-S process is not still taking place. At Bora, we have been working on continuous flow E-S manufacturing, with this process proving to be particularly well-suited to running continuously, offering considerable advantages at commercial scale. Although E-S manufacturing is already semi-continuous, a configuration as a completely continuous process has demonstrated that throughput can reach upwards of 200-300kg per hour.

    However, working with a continuous process requires working with a partner of suitable experience, as technical and operational experience is a prerequisite. In addition, the process requires a team that has invested in the best quality process room infrastructure, as controlling temperature and relative humidity are critical to ensure the final product is to the required standard.

    The demand for specialist expertise in this area continues to rise from drug developers, as they are increasingly seeking specialized outsourcing partners and solutions to manufacture and commercialize products. In the case of E-S, its ability to deliver safety, therapeutic efficacy and dose compliance across a range of therapeutic areas will likely see this only continue in the future. 

    References
    1.  https://www.fda.gov/industry/prescription-drug-user-fee-amendments/voice-patient-series-reports-fdas-patient-focused-drug-development-initiative
    2.  https://www.eupati.eu/
    3.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471246/

      Loading, Please Wait..
      Trending
      • Aurigene Expands Biologics CDMO Capacity
      • Astellas To Transfer Manufacturing Plant To Delpharm
      • Catalent Adds New Cryogenic Capabilities At Japanese Facility
      • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
      • Lifecore Biomedical Enters Into $150M New Financing Deal
      Breaking News
      • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
      • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
      • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
      • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
      • Waters Corp. Acquires Light Scattering Company Wyatt Technology
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
      BGG Receives Patent for Saw Palmetto ID Method
      Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
      Coatings World

      Latest Breaking News From Coatings World

      Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
      BCF Calls for Greater Urgency on REACH Impasse
      MNYCA Hosts Afternoon Baseball Event
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      CareDx, Miromatrix Collaborate on Bioengineered Organs Research
      Capitainer Releases to Market its Fully Automated Sample Handler
      Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
      JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
      Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Stetson Introduces Men’s Grooming Portfolio
      Two Executives Depart from Unilever Amid CEO Transition
      L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
      Happi

      Latest Breaking News From Happi

      Shaz and Kiks Launches at Sephora
      Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
      Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
      Ink World

      Latest Breaking News From Ink World

      ACTEGA, Makro Labelling to Advance Signite Technology
      BCF Requests Greater Urgency on REACH Impasse
      Updated Method Published for Entire BASF Product Portfolio
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      ACTEGA teams with Makro Labelling to advance Signite technology
      Constantia Flexibles and SB Packagings commence joint venture
      Inland donates new VersaStudio printer to local high school
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Mann+Hummel Names President Air Filtration Americas
      KNH Launches Eco-Friendly Menstrual Pads
      Niine Introduces India's First PLA-Based Sanitary Pads
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Enrollment Completed in Anika Therapeutics' Hyalofast Study
      Exactech Releases Next-Gen GPS Shoulder
      Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Presents Path to Accelerate Revenue Growth
      STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
      Graphene Flagship to Join Euro Nano Forum 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login